Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients with metastatic melanoma and BRAF mutation

Next Previous
Trial Profile

A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients with metastatic melanoma and BRAF mutation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 05 Nov 2024 According to a Nucleai media release, abstract in collaboration with Dr. Paolo Ascertio and Lunaphore, a Bio-Techne brand, examines the spatial proteomic profile of melanoma patients undergoing immunotherapy as part of the SECOMBIT trial will be presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting.
  • 14 Jun 2024 This trial has been Discontinued in Austria, according to European Clinical Trials Database record.
  • 06 Jun 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top